This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.
In the article entitled "Cost-Benefit Issues in the Practice of Internal Medicine" that appeared in the June 1991 issue of the Archives (1991;151:1165-1168), the nadolol dose on page 1166, column 1, lines 32-36, is listed as 40 mg three times daily. The sentence should have read as follows: "Among the most commonly used β-blocking agents, based on most recent wholesale prices, a 1-week course of nadolol (40 mg/d) and atenolol (50 mg/d) are approximately equivalent in cost and remain at least six times as expensive as propanolol hydrochloride (40 mg three times a day)."
Dosages and Cost-Benefit Comparisons of Drug Therapy. Arch Intern Med. 1991;151(11):2220. doi:10.1001/archinte.1991.00400110078016
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: